Neuren Pharmaceuticals Ltd (NEU.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Operating Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -10 | -40 | -19 | -10 | -6 |
| Purchase Of Investment | N/A | -211,445 | N/A | N/A | N/A |
| Sale Of Investment | 4,144 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $4,134 | $-211,485 | $-19 | $-10 | $-6 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,660 | 3,637 | N/A | 23,281 | 20,216 |
| Common Stock Repurchased | -10,435 | -18 | -2 | -1,106 | -1,075 |
| Financing Cash Flow | $-8,775 | $3,619 | $-2 | $22,175 | $19,141 |
| Exchange Rate Effect | 1,970 | -145 | -181 | 400 | -713 |
| Beginning Cash Position | 17,094 | 40,180 | 36,783 | 24,188 | 13,844 |
| End Cash Position | 3,153 | 17,094 | 40,180 | 36,783 | 24,188 |
| Net Cash Flow | $-15,911 | $-22,941 | $3,578 | $12,195 | $11,057 |
| Free Cash Flow | |||||
| Capital Expenditure | -10 | -40 | -19 | -10 | -6 |
| Free Cash Flow | -10 | -40 | -19 | -10 | -6 |